Extending FDA-approved cancer drug indications requires high patient numbers, study finds Post author: Post published:September 29, 2023 Post category:uncategorized Number of patient participants needed for secondary approval of a new cancer drug. You Might Also Like Testing nicotinamide riboside as a potential aid for long COVID recovery November 14, 2025 Pregnancy complications linked to higher long-term stroke risk in women June 23, 2025 Tenecteplase injection after clot removal improves stroke recovery February 8, 2025